Sucharita Mistry, PhD

CHIP was associated with higher rates of complete response and cytokine release syndrome.

Gemcitabine plus cisplatin reduced the risk of death by 28%.

Patients with BRCA1/2 alterations had the best response to talazoparib.

The overall response rate was 7.8%, and the disease control rate was 65%.

Starting screening at age 40 was linked to a reduced risk of death and was deemed cost-effective.

Most adverse events in the olaparib arm were manageable with supportive treatment or dose modifications.

Entinostat did not improve progression-free or overall survival.

PARP inhibitor use increased regardless of BRCA mutation status.

Adding temozolomide to vincristine and irinotecan improved survival.

Remetinostat produced a complete response in 17 of 33 tumors.